Nervous System News and Research

Latest Nervous System News and Research

U-M researchers identify how amlexanox drug improves metabolism of sugar

Researchers at the University of Michigan have identified how a promising drug in clinical trials for the treatment of obesity and related metabolic disorders improves the metabolism of sugar by generating a new signal between fat cells and the liver.

13 Jan 2015

TSRI researchers identify enzyme that produces inflammatory lipid molecules in the brain

A team led by scientists at The Scripps Research Institute has identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited neurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that inhibit this enzyme.

13 Jan 2015

Altos Therapeutics announces issuance of Mexican patent covering dopamine D2/D3 drug candidates

Altos Therapeutics, LLC announced today that the Mexican Institute of Industrial Property has issued Patent Number 323020 titled, "D2 Antagonists, Methods of Synthesis and Methods of Use". The patent broadly and specifically covers the company's dopamine D2/D3 drug candidates, their pharmaceutical compositions, and their use to treat a number of important gastrointestinal conditions in humans, such as gastroparesis.

12 Jan 2015

Personal gender identity of every human being is reflected in the structure of brain networks

Our sense of belonging to the male or female gender is an inherent component of the human identity perception. As a general rule, gender identity and physical sex coincide. If this is not the case, one refers to trans-identity or transsexuality. In a current study, brain researcher Georg S. Kanz of the University Clinic for Psychiatry and Psychotherapy of the MedUni Vienna was able to demonstrate that the very personal gender identity of every human being is reflected and verifiable in the cross-links between brain regions.

9 Jan 2015

FDA approves RYTARY for Parkinson's disease treatment

Impax Pharmaceuticals, a division of Impax Laboratories, Inc., today announced that the U.S. Food and Drug Administration approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication.

8 Jan 2015

Study: Synthetic triglyceride oil may provide hope for people with Huntington's disease

An early study suggests that a synthetic triglyceride oil called triheptanoin may provide hope for people with Huntington's disease. The study is published in the January 7, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology.

7 Jan 2015

FDA receives Actavis' NDA resubmission for cariprazine

Actavis plc (NYSE: ACT) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Actavis' New Drug Application (NDA) resubmission for its atypical antipsychotic cariprazine, a potent dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors.

6 Jan 2015

Study: Placental cells may possibly treat damaged nerves

New findings suggest that placental cells may potentially treat damaged nerves possibly leading the way to new treatment for stroke patients.

5 Jan 2015

New study finds that exercise may improve lives of Parkinson's disease patients

Exercise may help people with Parkinson's disease improve their balance, ability to move around and quality of life, even if it does not reduce their risk of falling, according to a new study published in the December 31, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology.

2 Jan 2015

Palatin begins bremelanotide phase 3 study for treatment of female sexual dysfunction

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has started its bremelanotide pivotal registration program.

29 Dec 2014

Newron, Zambon announce re-submission of safinamide NDA to FDA

Newron Pharmaceuticals S.p.A., a research and development company focused on novel CNS and pain therapies, and its commercial and development partner Zambon S.p.A., an international pharmaceutical company, announced today that the NDA for safinamide has been re-submitted to the US FDA.

29 Dec 2014

Actavis receives complete response letter for nebivolol/valsartan FDC for treatment of hypertension

Actavis plc today confirmed that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for the fixed-dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension.

25 Dec 2014

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Actavis plc and Adamas Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor.

25 Dec 2014

Deeper cooling does not reduce NICU death among newborns with hypoxic ischemic encephalopathy

Among full-term newborns with moderate or severe hypoxic ischemic encephalopathy (damage to cells in the central nervous system from inadequate oxygen), receiving deeper or longer duration cooling did not reduce risk of neonatal intensive care unit death, compared to usual care, according to a study in the December 24/31 issue of JAMA.

24 Dec 2014

Nervous System News and Research

Latest Nervous System News and Research

U-M researchers identify how amlexanox drug improves metabolism of sugar

TSRI researchers identify enzyme that produces inflammatory lipid molecules in the brain

Altos Therapeutics announces issuance of Mexican patent covering dopamine D2/D3 drug candidates

Personal gender identity of every human being is reflected in the structure of brain networks

FDA approves RYTARY for Parkinson's disease treatment

Study: Synthetic triglyceride oil may provide hope for people with Huntington's disease

FDA receives Actavis' NDA resubmission for cariprazine

Study: Placental cells may possibly treat damaged nerves

New study finds that exercise may improve lives of Parkinson's disease patients

Palatin begins bremelanotide phase 3 study for treatment of female sexual dysfunction

Newron, Zambon announce re-submission of safinamide NDA to FDA

Actavis receives complete response letter for nebivolol/valsartan FDC for treatment of hypertension

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Deeper cooling does not reduce NICU death among newborns with hypoxic ischemic encephalopathy

Researchers describe key group of small DNA fragments in neurone regulation and maturity

Muscle spindle sensory feedback promotes functional recovery after spinal cord injury

UCLA researchers uncover potential to restore lost memories in patients with early Alzheimer's

Scientists discover genetic pathway responsible for brain development

New nationwide effort seeks to find novel approaches to treat ASD, intellectual disability

UT Southwestern researchers find new potential target for halting tumor growth

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Nervous System News and Research

Latest Nervous System News and Research

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Newsletters you may be interested in